Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class ASSE: 600436

Announcement on Completion of 1st Subject Enrollment in Phase I Clinical Trials of PZH2113 Capsules

· Issued by Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Completion of 1st Subject Enrollment in Phase I Clinical Trials of PZH2113 Capsules

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment